Release of Customer Reference with Flagship Ventures: Lipid analysis for early stages of drug discovery

Fueled by curiosity and a quest for new sources of future value, Flagship conceives, creates, resources and grows first-in-category life sciences companies. The unique, systematic, hypothesis-driven innovation process empowers Flagship simultaneously to explore the world’s biggest problems and to conceive disruptive scientific solutions. Flagship ventures deliver breakthrough medicines, maximize the potential of new agricultural practices, and power the world with innovative resources. At Flagship Pioneering, we deploy boundless curiosity and creativity within our institutional innovation foundry, VentureLabs. Flagship VentureLabs has originated more than 200 patents and 40 companies. These ventures establish entire new fields and uncover previously undiscovered areas of science. Some of our notable venture creation successes include Moderna Therapeutics, Seres Therapeutics, Axcella Health, Indigo Agriculture and Adnexus.

About the project
Lipotype performed lipid analysis for Flagship VentureLabs with the aim to better understand molecular compositions of chondrisomes, pharmaceutically active derivatives of mitochondria. The research of Flagship VentureLabs is on novel ways of preparation of chondrisomes that have beneficial structural characteristics, yield, concentration, stability, viability, integrity, or function. The lipidomic results facilitated the characterization of isolated chondrisomes in order to evaluate their quality and subsequently were used to file a recently published patent application. 

Methods and Compositions of Chondrisomes – United States Patent Application 20170151287, 2017
G A Von Maltzahn, J M Milwid, M Mee, J R Rubens, D Chess, K Trudeau, K Mahdaviani, J Feala

Source: Press Release by Lipotype GmbH from September 13, 2017